



VIJAYA[®]
DIAGNOSTIC
CENTRE

May 07, 2026

To
The Listing Department,
National Stock Exchange of India Limited
NSE Symbol: VIJAYA

To
The Corporate Relations Department,
BSE Limited
BSE Scrip Code: 543350

Dear Sir/Madam,

Sub: Investor Presentation

Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the presentation on Financial Results for quarter and year ended March 31, 2026, which would be used in the Investors / Analysts earnings conference call scheduled to be held on **May 08, 2026, at 02:00 P.M. (IST)**.

Please take the information on record.

Thanking you,
For **Vijaya Diagnostic Centre Limited**

Ankit Shah
Chief Financial Officer

Encl.: As Above



**VIJAYA
DIAGNOSTIC
CENTRE** [®]



Q4 & 12M FY26 Earnings Presentation

May 7, 2026

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Vijaya Diagnostic Centre Limited (the ‘Company’)**, have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Note 1:

Merger (Medinova Diagnostic Services Limited, Kolkata) : Pursuant to the NCLT, Hyderabad Bench order dated 13 October 2025, Medinova Diagnostic Services Limited got merged with the Company effective 01 April 2024.

Accordingly, the financial numbers for the current period and previous period have accordingly been restated to reflect the amalgamation.



**VIJAYA
DIAGNOSTIC
CENTRE**



Q4 FY26 Performance Snapshot

Financial Performance

INR 2,194 Mn

Revenue from Operations

INR 955 Mn | 43.5%

EBITDA | EBITDA Margin %

INR 479 Mn | 21.8%

PAT | PAT Margin %

Key Metrics



1.21 Mn

Footfall

4.49 Mn

Tests



162 ⁽¹⁾

Centres



92%

B2C Revenue %



YOY Growth %

26.6%

Revenue Growth %

18.5%

Test Volume Growth %

15.8%

Footfall Growth %


38.7%

EBITDA Growth %


37.5%

PAT Growth %

Geographical Contribution



Wellness Share%



1. Total number of centres as at 31-Mar-26

Financial Performance

INR 8,142 Mn

Revenue from Operations

INR 3,369 Mn | 41.4%

EBITDA | EBITDA Margin %

INR 1,730 Mn | 21.2%

PAT | PAT Margin %

Key Metrics



4.68 Mn

Footfall

16.92 Mn

Tests



162 ⁽¹⁾

Centres



92%

B2C Revenue %



YOY Growth %

19.5%

Revenue Growth %

14.4%

Test Volume Growth %

11.7%

Footfall Growth %


23.3%

EBITDA Growth %


20.3%

PAT Growth %

Geographical Contribution



Wellness Share%



1. Total number of centres as at 31-Mar-26



Commenting on the Q4 & FY26 results and future business outlook, Ms. Suprita Reddy, MD & CEO at Vijaya Diagnostic Centre Ltd. said:

“FY26 was a landmark year for Vijaya, as revenues crossed INR 800 Cr, translating into a 16.5% CAGR over the five years since listing, outperforming our long-term guidance of 15%. EBITDA margins also remained ahead of our 40% guidance, reflecting disciplined execution. Over the same period, our network of centres doubled.


Q4 FY26 was particularly strong, with Vijaya reporting its highest-ever quarterly revenue of INR 219 Cr. Revenue grew ~26.5% YoY, supported by ~18.5% volume growth across the network. Growth was broad-based, driven by strong momentum in both pathology and radiology segments, supported by network expansion and improving brand acceptance in newer markets.

Our expansion strategy continues to deliver encouraging outcomes. The Khammam and Nandyal hubs achieved break-even within two quarters, while the Ambegaon hub in Pune achieved break-even within one year of launch, reinforcing our confidence in scaling newer geographies efficiently.


In FY27, we intend to further strengthen our presence through the addition of 4–5 hubs and 10–12 spokes. We are also setting up a fully automated laboratory with track infrastructure at Panjagutta, Hyderabad, which is expected to enhance turnaround times and operational productivity. Additionally, we plan to introduce advanced genomic testing capabilities as part of our specialised diagnostics offering.”

Key Financials


Revenue from Operations (INR Mn)



EBITDA & EBITDA Margin %




PAT & PAT Margin %




Revenue Mix


Radiology vs. Pathology Breakdown %




B2C Revenue %




Wellness share %




Tests Performed (# in Mn)




Footfalls (# in Mn)




Tests / Footfalls (#)



Revenue per Test (INR)



Revenue per Footfall (INR)



Consolidated Profit & Loss Statement

(INR Mn)

Particulars	Q4 FY26	Q4 FY25	Y-o-Y	Q3 FY26	Q-o-Q	FY26	FY25	Y-o-Y
Revenue from operations	2,193.8	1,732.4	26.6%	2,052.1	6.9%	8,142.0	6,813.9	19.5%
Cost of materials consumed	249.3	221.7	12.5%	240.3	3.8%	946.8	847.6	11.7%
Gross Profit	1,944.5	1,510.8	28.7%	1,811.9	7.3%	7,195.2	5,966.3	20.6%
Gross Profit (%)	88.6%	87.2%	143 bps	88.3%	34 bps	88.4%	87.6%	81 bps
Employee benefits expense	338.3	284.0	19.1%	330.4	2.4%	1,307.4	1,121.5	16.6%
Other expenses	650.9	538.1	21.0%	620.9	4.8%	2,518.4	2,112.6	19.2%
EBITDA	955.2	688.6	38.7%	860.5	11.0%	3,369.4	2,732.2	23.3%
EBITDA Margin (%)	43.5%	39.8%	379 bps	41.9%	161 bps	41.4%	40.1%	129 bps
Other income	24.0	55.5	-56.7%	51.0	-53.0%	208.0	183.2	13.5%
Depreciation and amortization expense	243.3	188.2	29.3%	243.4	0.0%	918.2	706.0	30.1%
EBIT	735.9	555.9	32.4%	668.2	10.1%	2,659.1	2,209.4	20.4%
Finance costs	93.2	71.9	29.7%	85.9	8.5%	332.3	267.4	24.3%
Profit before Exceptional Items & Tax	642.7	484.0	32.8%	582.2	10.4%	2,326.8	1,941.9	19.8%
Exceptional Items	0.0	10.3	-100.0%	0.0	-	0.0	10.3	-100.0%
Profit before Tax	642.7	473.7	35.7%	582.2	10.4%	2,326.8	1,931.6	20.5%
Tax expenses	163.4	125.1	30.6%	150.5	8.6%	597.0	493.7	20.9%
Profit before Minority Interest	479.3	348.6	37.5%	431.8	11.0%	1,729.8	1,437.9	20.3%
Minority Interest	0.0	0.0	-	0.0	-	0.0	0.0	-
Profit after Tax (PAT)	479.3	348.6	37.5%	431.8	11.0%	1,729.8	1,437.9	20.3%
PAT Margin (%)	21.8%	20.1%	172 bps	21.0%	81 bps	21.2%	21.1%	14 bps
EPS – Basic (INR)*	4.7	3.4	37.4%	4.2	11.0%	16.8	14.0	20.2%

*Not annualized

1

High Volume of Wellness testing being observed in younger population due to **increased awareness & growing chronic disease burden** due to stress, sedentary life & shift in lifestyle patterns

2

Adoption of wellness testing is scaling across markets, with **Tier 2 and Tier 3 cities** emerging as key growth drivers

3


Digital promotions by the organised players along with third party healthcare platforms have also aided in increased footfalls for wellness packages

4


Faster report turnaround times (TAT), coupled with the **convenience of home testing**, have been key drivers of growth



Q4 FY26 YOY Growth %



FY26 YOY Growth %





**VIJAYA
DIAGNOSTIC
CENTRE**



Key Developments



New CRM – Enabling 360° Relationship Management



- **Intelligent lead** & engagement workflows with **personalized** outreach campaigns
- Enhanced sales velocity with **automated campaigns, and insights**
- **Seamless omnichannel experience** across Website, Partner Portal & call center

Transforming Operations through new ERP



- **Integration** of finance, procurement, supply chain & operations departments
- **Automated** inventory, consumables, reagent management
- **Real-time** financial visibility and compliance

AI-Driven Solutions Elevating Diagnostic Excellence



- **AI-Enabled Radiology** Workflow improving productivity of radiologists
- **CT KUB AI** offering intuitive, system-wide visualization to enable accurate reporting
- **CBCT Dental AI** for precise 3D analysis & high-quality automated reports

Company is undergoing a strategic digital evolution to build a secure, scalable, AI-ready, patient-first healthcare ecosystem



Automated Stone Detection & 3D Localization

- Auto-locates & measures stones
- Precise 3D localization of stones aids in anatomical orientation



Intelligent Differentiation

- Distinguishes true kidney stones from harmless pelvic vein calcifications and vascular spots in arteries




Improving Radiologist's Productivity & Accuracy

- Prioritises urgent scans - flagging positive cases
- Cuts reporting time with precise volume & density data
- Reduces risk of missing small or faint stones



Enhances Precision Surgical Planning for Urologist

- Precise volume and density data helps in choosing the right intervention
- Accurate "stone burden" calculation allows for better prediction of stone-free rates after a single procedure





Key Slices:

Stone Composition:

- Soft (Below 200 HU)
- Uric (200-600 HU)
- Calcium (Above 600 HU)

Incorporating AI has enhanced the surgical planning experience, and improves operational efficiency across the entire Urology pathway



- AI dental diagnostics platform delivers **high-precision 2D/3D radiograph analysis, predictive care, and clinical decision support**
- **AI-based 2D & CBCT scan analysis** for faster, more accurate diagnostics
- Enhances **patient outcomes & trust** with **visual decisions support**
- Enables **predictive care & personalized treatment planning**



**VIJAYA
DIAGNOSTIC
CENTRE**




Strategic Expansion



Inorganic Expansion Strategy

- Successfully acquired PH, Pune's largest B2C integrated diagnostic chain
- This strategic acquisition seamlessly aligns with our commitment to providing top-notch healthcare services at affordable price, reflecting our shared cultural values
- Operationalized 2 hubs in Ambegaon & Kalyani Nagar and 2 spokes under Vijaya PH Brand, following the acquisition
- Aspire to consolidate our presence gradually by building a denser network



East India Strategy

- Inaugurated 5 hubs in FY26 under the Vijaya brand in West Bengal
- Employing our proven hub and spoke model, aim to replicate our success in East India by creating a dense network

Core Market Strategy


- Embracing our hub-and-spoke model, we aim to broaden our presence in concentric circles, strategically reaching Tier 1 and Tier 2 cities within AP and Telangana where our brand is highly esteemed
- Planning to add multiple spokes across the region in FY27

Expansion into Neighbouring State

- Inaugurated 2 hubs in HSR Layout and Yelahanka, Bengaluru in Q1 FY26
- Planning to add few more hubs in FY27

Expansion Plans - Upcoming Hubs and Spokes Centres

Geography	Count & Type	Tentative Timelines for Commencement
Hyderabad	5 Spokes	H1 FY27
RoAPT	2 Spokes 1 Hub	H1 FY27 H2 FY27
Bengaluru	2 Hubs 1 Hub	H1 FY27 H2 FY27
West Bengal	2 Spokes	H2 FY27
Pune	1 Spoke	H1 FY27





**VIJAYA
DIAGNOSTIC
CENTRE**




Company Overview



Vijaya Diagnostic is the largest integrated B2C focused diagnostic chain in India with 162 state-of-the-art centres spread across 27 cities & towns

Evolved from a regional player to a player with presence in multiple geographies ...



... While retaining its core values of providing Quality, Reliable & Accurate Diagnostic services at Affordable prices



40+
Years of Vintage



Founded by Mr. Surendranath Reddy in 1981 and currently led by Ms. Suprita Reddy



27
Cities and towns across India

Largest B2C integrated Player in India



350+
Doctors

Radiologist & Pathologist network



~4.68 Mn
Footfalls ⁽¹⁾


Trusted by every Age group



~16.92 Mn
Tests ⁽¹⁾

Most preferred Diagnostic Centre

1. Footfall and Tests for the 12 months ended 31-Mar-26



* ICMR: Indian Council of Medical Research; NSE: National Stock Exchange, BSE: Bombay Stock Exchange

Complete Range of Diagnostic Services under One Roof

Robust operational network enables us to offer integrated, high-quality diagnostic services that significantly elevate the customer experience





Pathology (1) 63.2 %

Radiology (1) 36.8 %

Vijaya has been successful in creating a dense market consolidating its foothold in its core geographies of AP & Telangana markets

Present in Key Geographies of AP & Telangana



67 (1) %

Hyderabad Revenue Contribution




20 (1) %

RoAPT Revenue Contribution


A dense network created across AP & Telangana aids in distributing patient load and offering significantly faster TAT across tests

Differentiated offering has accelerated Vijaya's success in new geographies




Faster break-even's enable replication of densification strategy in newer geographies

Differentiated offering has accelerated Vijaya Brand's success in new geographies




Pune Network




Faster break-even's enable replication of densification strategy in newer geographies





Differentiated offering has accelerated Vijaya Brand's success in new geographies



Faster break-even's enable replication of densification strategy in newer geographies




Geographical Revenue Mix





Vijaya is well-placed to attract customers in new geographies due to its integrated offering and strong emphasis on customer experience

Online Services

Enhancing Customer Experience through Seamless Online App, E-Commerce Website and Call Centre Bookings



- Access to reports online & historical medical records
- Intuitive⁽¹⁾ & user-friendly interface
- Agile customer service team
- High Brand salience
- High customer stickiness
- Organic word of mouth growth



Home Collections

Elevating Customer Experience through Home Collections




Seamless & Efficient process **Temperature Controlled Logistics** **High standards of hygiene maintained**



Pre-sealed & sterilized single-use home kit

Reaches Lab within 2 hours⁽²⁾

1. Patient can track his / her health trends over time 2. Post Collection



Advanced Software to Manage Clinical Data

Advance Laboratory Information Management System (LIMS)

Fully Integrated Radiology Information Systems (RIS) and Picture Archive and Communication Systems (PACS)

Key Suppliers

- Long standing relationship with medical technology vendors
- At the forefront of introducing new tests by adopting the latest medical technologies
- Among the first diagnostic service provider in South India to offer PET-CT scan in 2008

Front end IT infrastructure enabling...

Standardization across our operations

Closely track key performance metrics and maintain the **Turn-Around Time (TAT)**

Reduce incidence of errors due to **Low Human Intervention**

Monitor Technical Operations

Provide **Uniform Experience** to customers from booking appointments to accessing reports online

Vijaya has been ahead of the curve in getting best-in-class & latest diagnostic equipment in India which has helped in offering high quality services



Founder & Chairman

Dr. S. Surendranath Reddy

- ✓ 40+ years of experience
- ✓ Holds Bachelor's degree in Medicine and Doctor of Medicine in Radiology



Managing Director & CEO

Ms. Suprita Reddy


- ✓ 22+ years of experience
- ✓ Awarded Women Leadership Award in Healthcare by ABP



Executive Director

Mr. Sunil Chandra Kondapally

- ✓ 22+ years of experience
- ✓ Holds Bachelor's degree in Electrical Engineering from Florida State University



Non-Executive Director

Ms. S Geeta Reddy

- ✓ 35+ years of experience
- ✓ BOD at Sura Agritech, Iffco Kisan, Namrata Diagnostics, etc.
- ✓ LLB from Osmania University



Non-Executive Independent Director

Dr. D Nageswar Reddy

- ✓ Chairman of AIG⁽¹⁾, Hyderabad
- ✓ Received Padma Shri & Padma Bhushan from Govt of India
- ✓ D.M⁽²⁾ from PGIMER Chandigarh



Non-Executive Independent Director

Mr. Shekhar Prasad Singh

- ✓ 40+ years of experience
- ✓ Ex-Chief Secretary to Government of Telangana
- ✓ Retired IAS officer of 1983 batch



Non-Executive Independent Director

Mr. S. Murthy Chavali

- ✓ 35+ years of experience
- ✓ Ex-CEO - Aurigene Discovery Tech
- ✓ MBA from IIM, Bangalore & BTech from IIT, Madras



Non-Executive Independent Director

Dr. Manjula Anagani

- ✓ 25+ years of experience
- ✓ Clinical Director & HOD - Centre of women & childcare - Care hospitals
- ✓ Awarded Padma Shri by GOI



Non-Executive Independent Director

Mr. Ravi Shankaramiah

- ✓ 40+ years of experience and designated as Senior Advocate by High Court of Andhra Pradesh
- ✓ Graduated magna cum laude from USC, LA⁽³⁾ in MS



Non-Executive Independent Director

Dr. Sasikala Paruchuri Kola

- ✓ 30+ years of experience as a Gynaecologist & Obstetrician
- ✓ Leadership roles in FOGSI⁽⁴⁾ and OGS⁽⁵⁾
- ✓ MD & DGO from Osmania Medical College



Founder & Chairman

**Dr. S. Surendranath
Reddy**



Managing Director & CEO

Suprita Reddy



Executive Director

**Sunil Chandra
Kondapally**



Chief Operating Officer

**Sivaramaraju
Vegesna, CFA**



Chief Financial Officer

Ankit Shah



Chief Technology Officer

Sai Prasad



Director - Laboratory


Dr. Kiran B



Director - Radiology

Dr. V Vijayanand

Shareholding Pattern as at 31st March, 2026



DIIs: Mutual Funds, AIFs and QIBs
 FIIs: Hedge Funds, Sovereign Wealth Funds, Foreign MFs, Pension Funds, Trusts and AMCs
 Others: Retail, Bodies Corporate and others

Free Zoom Webinar | Live on YouTube | LinkedIn | Vdc Connect

Webinar on Coagulation work up in clinical laboratories

8th January, 2026 (Thursday) | 4:00 PM IST

Speaker
Dr. Suvarna Pai
MBBS, MD Pathology
Consultant Pathologist
Vijaya Diagnostic Centre, Hyderabad

Moderator
Dr. Sreedevi D
HOD & Senior
Consultant - Hematology
Vijaya Diagnostic Centre, Hyderabad

Free Zoom Webinar | Live on YouTube | LinkedIn | Vdc Connect

Webinar on MRI in pericardial diseases and cardiac masses

23rd January, 2026 (Friday) | 4:00 PM IST

Chief Guest
Dr. Narsa Raju Kavalipati
MBBS, MD (General Medicine),
DM (AIMS New Delhi),
FACC Sr. Consultant Cardiology
& Director Interventional
Cardiology - CARE Hospitals,
Banjara Hills, Hyderabad

Speaker
Dr. Deepak B
MD, DNB, DMRD,
EDIR (Europe), FRCR (UK)
Senior Consultant Radiologist
at Vijaya Diagnostic Centre,
Hyderabad

Moderator
Dr. GA Prasad
MBBS, DMRD, DNB
Senior Consultant Radiologist
at Vijaya Diagnostic Centre,
Hyderabad

Free Zoom Webinar | Live on YouTube | LinkedIn | Vdc Connect

Webinar on Neurometabolic and Toxic Encephalopathy

13th February, 2026 (Friday) | 4 PM IST

Chief Guest
Dr. K. Hemant Kumar
MBBS, MD (General Medicine),
DM (Neurology) Gold Medalist
in DM Neurology
Consultant Neurologist, Brain and
Spine Centre, Kumool and Kumool
Heart and Multiplespecialty Hospital.

Speaker
Dr. Arpit Shantagiri
MD, DNB Radiodiagnosis and
Interventional Radiology,
Fellow in Neuro Radiology.
Consultant Radiologist,
Vijaya Diagnostic Centre, Bengaluru.

Moderator
Dr. Mohd Abdul Khalid
MD, DNB Radiodiagnosis,
Fellow in Paediatric Radiology,
Consultant Radiologist,
Vijaya Diagnostic center, Hyderabad.

Free Zoom Webinar | Live on YouTube | LinkedIn | Vdc Connect

Webinar on Ultrasound Scrotum in Infertility

13th March, 2026 (Friday) | 4 PM IST

Chief Guest
Dr. G. Rahul Reddy
MBBS, MS, DNB
Fellowship in Andrology &
Men's Health.
Consultant Micro Surgical
Andrologist, Hyderabad.

Speaker
Dr. Abhijeet Gourishetty
MD (Radiology),
Consultant Radiologist,
Vijaya Diagnostic Centre,
Hyderabad.

Moderator
Dr. Sai Kotamraju
MD (Radiology),
Consultant Radiologist,
Vijaya Diagnostic Centre,
Hyderabad.





**VIJAYA
DIAGNOSTIC
CENTRE**



Annexure



State-of-the-art Infrastructure (1/3)










Advanced Equipment in Place to Deliver High Quality Services (1/2)




Advanced Equipment in Place to Deliver High Quality Services (2/2)




Diagnostic Centre (Nos)




Footfalls (Mn)




Tests Performed (Mn)




Test per Footfall (Nos)




Revenue per Test (INR)




Revenue per Footfall (INR)




Revenue




EBIDTA




PAT



EBIDTA Margin (%)




PAT Margin (%)




Integrated business model with high B2C concentration (~92%) and a strong brand recall has resulted in Industry leading margins


Surplus Cash (INR Mn)




CFO ⁽¹⁾ / EBIDTA (%)



RoCE Pre-Tax ⁽²⁾ (%)



RoE ⁽³⁾ (%)



1. CFO = Cash flow from Operations

2. ROCE (Pre-tax): (PBIT ex Other income) / (Average Network + Average Long Term Lease Liabilities – Average Surplus Cash)

3. ROE: PAT / Average Network

Consolidated Profit & Loss Account

(INR Mn)

Particulars	FY22	FY23	FY24	FY25	FY26
Revenue from operations	4,624	4,592	5,478	6,814	8,142
Cost of materials consumed	715	589	654	848	947
Employee benefits expense	707	785	902	1,122	1,307
Other expenses	1,165	1,398	1,712	2,113	2,518
EBITDA	2,037	1,820	2,209	2,732	3,369
EBITDA %	44.1%	39.6%	40.3%	40.1%	41.4%
Other income	128	142	208	183	208
Depreciation and amortization expense	527	617	570	706	918
EBIT	1,638	1,344	1,847	2,209	2,659
Finance costs	165	209	240	267	332
Profit before tax and exceptional items	1,474	1,135	1,607	1,942	2,327
Exceptional items	-	-	21	10	-
Profit before Tax	1,474	1,135	1,587	1,932	2,327
Tax expenses	367	283	390	494	597
Profit after Tax before Minority Interest	1,107	852	1,196	1,438	1,730
Minority Interest	10	5.8	8	-	-
Profit after Tax	1,097	846	1,188	1,438	1,730
PAT %	23.7%	18.4%	21.7%	21.1%	21.2%
EPS – Basic (INR)	10.76	8.29	11.62	13.95	16.81

(INR Mn)

ASSETS	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
NON-CURRENT ASSETS	4,436	5,777	7,714	9,664	11,851
Property, plant and equipment	1,966	2,940	3,785	4,469	5,625
Capital work-in-progress	341	271	83	703	343
Goodwill	53	53	1,192	1,192	1,192
Other intangible assets	14	22	207	219	204
Right of use asset	1,672	2,223	2,235	2,768	3,672
Intangible assets under development	1	6	5	0	8
Financial assets					
- Investments	0	0	0	0	0
- Other financial assets	75	90	113	165	481
Deferred tax assets	89	83	29	0	0
Income tax assets	2	2	2	12	2
Other assets	223	85	62	136	324
CURRENT ASSETS	2,698	2,757	2,113	3,072	3,219
Inventories	43	20	52	49	49
Financial assets					
- Investments	542	1,390	1,091	1,846	2,284
- Trade receivables	98	95	162	148	209
- Cash and cash equivalents	110	242	222	128	397
- Bank balances other than Cash and cash equivalents	1,813	922	508	361	131
- Loans	0	0	0	0	
- Other financial assets	51	36	31	478	80
Other current assets	41	51	46	62	70
TOTAL ASSETS	7,135	8,534	9,828	12,736	15,070

EQUITY & LIABILITIES	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
EQUITY	4,695	5,466	6,599	7,991	9,572
Equity share capital	102	102	102	103	103
Instruments entirely equity in nature	-	-	-	-	-
Other equity	4,593	5,364	6,497	7,889	9,469
Non-Controlling Interest					
NON-CURRENT LIABILITIES	1,778	2,406	2,500	3,119	4,260
Financial liabilities					
- Borrowings	0	0	0	0	0
- Lease liabilities	1,703	2,330	2,391	2,964	4,000
- Other financial liabilities	0	0	0	0	0
Provisions	74	71	106	99	110
Other non current liabilities	1	5	3	3	5
Deferred tax liabilities	-	-	-	53	145
CURRENT LIABILITIES	661	662	729	1,626	1,239
Financial liabilities					
- Borrowings	6	0	0	0	0
- Lease liabilities	126	145	201	232	226
- Trade payables	216	277	329	331	376
- Other financial liabilities	248	140	114	925	491
Income tax liabilities	9	24	12	35	9
Provisions	21	40	32	60	83
Other current liabilities	35	36	40	44	53
TOTAL EQUITY AND LIABILITIES	7,135	8,534	9,828	12,736	15,070

(INR Mn)

Particulars	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
Cash Flow from Operating Activities					
Profit before Tax	1,474	1,135	1,587	1,932	2,327
Adjustment for Non-Operating Items	572	683	599	786	1,070
Operating Profit before Working Capital Changes	2,046	1,818	2,186	2,718	3,397
Changes in Working Capital	-67	90	-14	-74	-168
Cash Generated from Operations	1,979	1,908	2,172	2,644	3,228
Less: Direct Taxes paid	-399	-262	-339	-399	-522
Net Cash from Operating Activities	1,580	1,646	1,833	2,245	2,706
Purchase and construction of property, plant and building (net)	-1,223	-1,248	-880	-955	-1,827
Acquisition of subsidiary	-	-	-1,475	-	-
Investments (net)	-127	734	530	-893	57
Others	120	887	401	29	28
Cash Flow from Investing Activities	-1,231	-1,096	-1,423	-1,819	-1,742
Cash Flow from Financing Activities	-306	-419	-445	-520	-695
Net increase/ (decrease) in Cash & Cash equivalent	44	131	-36	-94	269
Cash & Cash Equivalents at the beginning of the period	67	110	258	222	128
Cash & Cash equivalents at the end of the period	110	242	222	128	397

Surplus Cash

Particulars	Mar-22	Mar-23	Mar-24	Mar-25	Mar-26
Investments*	542	1,390	1,092	1,846	2,284
Cash and cash equivalents	110	242	222	128	397
Bank balances other than Cash and cash equivalents**	1,813	922	537	843	512
Less: Deferred Capital Creditors				750	323
Total	2,465	2,554	1,851	2,067	2,869

*Current investments + investments with maturity more than 12 months (part of other non-current financial assets)

** Includes all the fixed deposits



**VIJAYA
DIAGNOSTIC
CENTRE**

Thank You

For further information please contact:

Mr. Dhiren Gala
AGM - Strategy & Investor Relations
+91 90598 93206

dhiren.g@vijayadiagnostic.in
ir@vijayadiagnostic.in

www.vijayadiagnostic.com



Corporate Office : #6-3-883/F, FPA Building, Near Topaz Building, Punjagutta, Hyderabad-500082, Telangana, India.